Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1

Belite Bio (NASDAQ:BLTE) is one of the best up and coming stocks with highest upside potential. On April 21, Belite Bio begun a rolling submission of an NDA to the FDA for tinlarebant, a potential first-ever treatment for Stargardt disease type 1/STGD1. This rare, progressive genetic disorder leads to legal blindness and currently has no approved therapeutic options. Using its Breakthrough Therapy Designation, Belite expects to complete the full application by Q2 2026.

The submission is supported by data from the Phase 3 DRAGON trial, which showed tinlarebant’s ability to slow retinal degeneration. As an oral therapy, tinlarebant works by reducing the levels of serum retinol binding protein 4/RBP4, effectively limiting the accumulation of vitamin A-based toxins in the eye. Beyond Stargardt disease, the drug is also being investigated for its potential to treat geographic atrophy, an advanced form of dry age-related macular degeneration.

In anticipation of a potential launch in 2027, the company is scaling its commercial infrastructure, including market access, medical affairs, and sales teams. Belite Bio (NASDAQ:BLTE) remains focused on working closely with the FDA throughout the review process to address the significant unmet medical needs of the Stargardt community.

Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1

Belite Bio (NASDAQ:BLTE) is a clinical-stage drug development company advancing novel oral therapeutics for degenerative retinal and metabolic diseases with significant unmet medical needs. Its lead candidate, tinlarebant, targets the reduction of bisretinoid toxins and is currently undergoing multiple clinical trials for Stargardt disease and geographic atrophy.

While we acknowledge the risk and potential of BLTE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BLTE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.